Clinical trials: Lenvatinib Treatment
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
- Trial name
- TREMENDOUS-2 (NCT07081633)
- Testing
- Durvalumab, Tremelimumab, Lenvatinib
- Where
- 23 sites in China, Hong Kong
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
HCC - Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
- Trial name
- Neo-LENTIS (NCT07475026)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Biliary tract carcinoma (BTC) is a highly aggressive malignancy with rising incidence worldwide. Most patients present at an advanced stage and have a dismal prognosis.
- Trial name
- NCT07530445
- Testing
- Drug: QL1706 5mg/kg, iv drip,d1,Q3W; Albumin-Bound Paclitaxel 125mg/m2, iv drip, d1、d8, Q3W; Lenvatinib 8mg, po, QD
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
This is a multicenter, Single-arm, Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combined with Tislelizumab (Triple Therapy) for patients with Hepatocellular…
- Trial name
- NCT06602011
- Testing
- TACE, Lenvatinib, combined with Tislelizumab group
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
GIST
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
- Trial name
- LONGIST (NCT07096609)
- Testing
- Lenvatinib Capsules
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Biliary Tract Neoplasms Immunotherapy
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
- Trial name
- NCT06230471
- Testing
- Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）, Pembrolizumab and Lenvatinib, Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Objective Response Rate (ORR)
Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma
TACE lays a theoretical foundation for synergistic enhancement in combination with PD-1/PD-L1 immunosuppressive agents by reducing tumor burden and peripheral blood treg, improving the immune status of patients, reducing immune…
- Trial name
- NCT05582109
- Testing
- Envafolimab, Lenvatinib Combined With TACE
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
The purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer.
- Trial name
- NCT04776148
- Testing
- pembrolizumab, lenvatinib, regorafenib
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 563 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
This phase II, multicenter, single-arm, open-label study evaluates first-line ipilimumab N01 plus sintilimab and lenvatinib in patients with locally advanced or metastatic TFE3-rearranged renal cell carcinoma (TFE3-rRCC), a rare…
- Conditions
- Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT07715565
- Testing
- Ipilimumab Injection, Sintilimab injection, Lenvatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- West China Hospital
Resectable Hepatocellular Carcinoma
Neoadjuvant Triple Therapy for Resectable HCC
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple…
- Trial name
- TALENP001 (NCT06569498)
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
Unresectable Hepatocellular Carcinoma
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with…
- Trial name
- IMbrave251 (NCT04770896)
- Testing
- Atezolizumab, Lenvatinib, Sorafenib
- Where
- 124 sites in Austria, Belgium and 26 more
- Volunteers
- 557 people
- Sponsor
- Hoffmann-La Roche
Endometrial Neoplasms
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer.
- Trial name
- NCT03517449
- Testing
- Pembrolizumab, Lenvatinib, Paclitaxel
- Where
- 169 sites in United States, Argentina and 19 more
- Volunteers
- 827 people
- Sponsor
- Eisai Inc.
Hepatocellular Carcinoma
Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib as first-line treatment in patients with advanced HCC.
- Trial name
- CASTLE-10 (NCT05897268)
- Testing
- Cryoablation, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Advanced Cholangiocarcinoma
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to…
- Trial name
- NCT05532059
- Testing
- Lenvatinib, tislelizumab, gemcitabine and cisplatin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intrahepatic Cholangiocarcinoma
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus Sintilimab in patients with advanced liver cancer progressed after treatment with immune checkpoint inhibitors.
- Trial name
- NCT05010681
- Testing
- Sintilimab, Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Advanced Biliary Tract Cancer
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers and to analyze potential biomarkers…
- Trial name
- NCT04211168
- Testing
- Toripalimab plus Lenvatinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Peking Union Medical College Hospital
Urologic Neoplasms
A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma
Study Design Prospective, single-arm, multicenter clinical study. Study Drugs Neoadjuvant phase: QL1706 (Aipaluo Tuoworilimab, an anti-PD-1/CTLA-4 combination antibody) plus lenvatinib. Adjuvant phase: QL1706 monotherapy.
- Trial name
- NCT07741617
- Testing
- Iparomlimab and Tuvonralimab in combination with Lenvatinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Renal Cell Carcinoma (RCC)
Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)
The PLUTO-trial is a single-center, open-label, phase II trial investigating Toripalimab plus Lenvatinib in patients with multi-stage clear-cell renal cell carcinoma.
- Trial name
- PLUTO (NCT06114940)
- Testing
- Toripalimab, Lenvatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Jinling Hospital, China
Biliary Tract Tumor
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
This study is a single-center, single-arm, open-label clinical study. All patients with advanced and unresectable biliary tract tumors will be treated with the combination of tisleizumab, lenvatinib and XELOX regimen (oxaliplatin…
- Trial name
- NCT05291052
- Testing
- Tislelizumab, Lenvatinib, Oxaliplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
TACE(transcatheter arterial chemoembolization) has been recommended by domestic and international guidelines as the standard treatment for a subset of HCC patients with very high heterogeneity, including BCLC stage…
- Trial name
- NCT05220020
- Testing
- TACE(Transcatheter arterial chemoembolization), Lenvatinib
- Where
- China
- Volunteers
- 299 people
- Sponsor
- Sun Yat-sen University